55 results about "Pegylated interferon" patented technology

Systems and methods are provided for predicting patient response to a therapy regimen for a liver disease or a disease that is treatable with an immunomodulatory disease therapy using gene expression classifiers. Systems and methods for screening for modulators of target gene expression are also provided. Systems and methods for developing therapeutics against one or more of the proteins coded for by genes of the present invention are also provided. Systems and methods for predicting a patient response to a regimen of pegylated interferon alpha and ribavirin in a therapy for hepatitis C viral infection are also provided.

A method of treating, preventing or ameliorating one or more symptoms associated with hepatitis C virus (HCV) in a patient in whom either the HCV is of Genotype 1 and/or the patient was previously treated with interferon and the previous interferon therapy was ineffective to treat the one or more symptoms associated with HCV, comprising administering to such a patient an effective amount of at least one compound of formulae I-XXVI of which the following structural formula is exemplary

or a pharmaceutically acceptable salt, solvate or ester thereof. Optional combined administration of said at least one compound with an interferon or pegylated interferon and/or ribaviron is also contemplated.

The present invention relates to lyophilized formulations of pegylated interferon which are prepared using trehalose as a cryoprotectant. The formulations have a low moisture content, which helps stabilize the pegylated interferon during storage of the formulations at room temperature. In addition, methods for preparing these formulations are provided.

A method of treating a patient infected with a hepatitis C virus to decrease the severity of the viral infection. The method comprises concomitantly administering over a given period of time to the patient a first component and a second component. The first component consists of a pharmaceutical composition containing as an active ingredient a pharmaceutically acceptable salt or prodrug of mycophenolic acid in a therapeutically effective amount to decrease the severity of the viral infection. The second component consists of an injection solution containing as an active ingredient interferon-alpha or pegylated interferon-alpha in a therapeutically effective amount to decrease the severity of the viral infection. The components are concomitantly administered over a period of time at least sufficient to reduce the amount of HCV-RNA present in the peripheral blood of said patient to less than 100 copies/ml at 24 weeks after the end of treatment.

The invention relates to combination therapies for the treatment of hepatitis C virus with telaprevir and pegylated interferon alfa-2a with or without ribavirin. The invention relates to the treatment of patients with bridging fibrosis infected with HCV using the combination therapy.

The invention discloses a recombinant bovine peginterferon α, a fusion protein for preparing the peginterferon and a preparation method thereof. The fusion protein is formed by connecting bovine interferon γ and bovine interferon α through a flexible linker, and the fusion protein is connected with bovine interferon α. After the lyoprotectant is mixed, the recombinant bovine peginterferon α can be obtained by lyophilization. The recombinant bovine long-acting interferon alpha can significantly increase the half-life of bovine interferon, which is more than 11 times higher than that of common bovine interferon, has broad-spectrum antiviral effect and can improve the immune response of cattle itself.

The invention discloses a fusion protein composed of porcine albumin and porcine interferon gamma, a preparation method thereof and a recombinant porcine peginterferon gamma. The fusion protein is composed of porcine albumin and porcine interferon gamma through a flexible linker The recombinant porcine long-acting interferon gamma can be obtained by lyophilizing after the fusion protein is mixed with the freeze-drying protective agent. The recombinant porcine long-acting interferon gamma can significantly increase the half-life of porcine interferon, which is more than 18 times higher than that of ordinary porcine interferon gamma, has broad-spectrum antiviral effect and can improve the immune response of pigs themselves.

The invention discloses a fusion protein composed of ovine albumin and ovine interferon gamma, a preparation method thereof and a recombinant ovine long-acting interferon gamma. The fusion protein is composed of ovine albumin and ovine interferon gamma through a flexible linker The recombinant sheep peginterferon gamma can be obtained after mixing the fusion protein with the freeze-drying protective agent and freeze-drying. The recombinant sheep long-acting interferon gamma can significantly increase the half-life of sheep interferon, which is more than 12 times higher than that of ordinary sheep interferon gamma, has broad-spectrum antiviral effect and can improve the immune response of sheep itself.

The invention discloses a recombinant canine peginterferon, a fusion protein for preparing the peginterferon and a preparation method thereof. The fusion protein is formed by connecting canine interleukin 2 and canine interferon α through a flexible linker. The recombinant canine peginterferon can be obtained after the protein is mixed with the freeze-drying protective agent and freeze-dried. The recombinant canine peginterferon can significantly increase the half-life of canine interferon, which is more than 10 times higher than that of ordinary canine interferon, has broad-spectrum antiviral effect and can improve the immune response of canine itself.

This invention relates to the use of specific dosing regimens of telaprevir in combination with peg-IFN and RBV in the treatment of HCV patients, wherein the treatment comprises (a) a lead-in phase of administering to the subject pegylated interferon and ribavirin, and (b) a treatment phase of administering to the subject a combination of telaprevir, pegylated interferon and ribavirin.

The invention relates to a novel antiviral drug composition and a method for curing hepatitis c virus (HCV) infection by using the novel type antiviral drug composition. The novel antiviral drug composition comprises 1 - (4-fluorine phenyl) - (3R)- [3 - (4 - fluorine phenyl) - (3S) - hydroxypropyl] - (4S) - (4 - hydroxypropyl) - 2-acrylic amide (ezetimibe, structural formula presented as graph 1) or acceptable derivatives in pharmaceutic preparation thereof, and an HCV resisting drug which is a drug composition selected from one kind or multiple kinds of boceprecir (BOC), telaprevir (TVR), pegylated interferon alpha (PEG - IFN alpha), interferon (IFNO) and ribavirin.

The invention discloses recombinant ovine pegylated interferon tau, fusion protein for preparing the same and a preparation method of the fusion protein. The fusion protein is formed by connecting sheep interferon gamma and sheep interferon tau through a flexible linker, and the recombinant sheep pegylated interferon tau can be obtained from the fusion protein and a freeze-drying protective agent through mixing and freeze-drying. The recombinant sheep pegylated interferon tau can significantly prolong the half-life of the sheep interferon, the half-life is prolonged 10 times or higher compared with that of normal sheep interferon, and the recombinant sheep pegylated interferon tau has a broad-spectrum antiviral effect and can improve immune response of sheep.

This invention provides a method for preparing dendritic cells from monocytes with the use of interferon α via non-adhesive culture. The method for preparing cytotoxic dendritic cells from monocytes comprises subjecting monocytes which were isolated from the peripheral blood to non-adhesive culture in the presence of GM-CSF and pegylated interferon α, and further conducting non-adhesive culture with the addition of prostaglandin E2 and OK432.

The invention discloses a pegylated interferon injection and a preparation method thereof. The pegylated interferon injection comprises pegylated interferon and auxiliary materials and is characterized in that a stabilizer in the auxiliary materials is a combination of Tween-80 and sodium ethylenediamine tetracetic acid; the pegylated interferon is any one of pegylated interferon alpha 1b, pegylated interferon alpha 2a and pegylated interferon alpha 2b, and the stock solution purity of the pegylated interferon is more than or equal to 95 percent. The specific combination of the Tween-80 and the sodium ethylenediamine tetracetic acid is used as a protein stabilizer, the risk caused when human blood albumin is used as a stabilizer is effectively avoided, and the identical stable effect can be achieved; relative to a Tween-80 and benzyl alcohol stabilizer system, the specific combination of the Tween-80 and the sodium ethylenediamine tetracetic acid is safer and more stable, so that the safety and the stability of the injection are improved, the finished injection product can be subjected to detection and control in terms of protein purity and content, and the product quality is truly guaranteed. The preparation method is simple, raw materials and the auxiliary materials are well sourced, and the manufacturing cost of the pegylated interferon injection is reduced.

The invention discloses chicken albumin-interferon-α-interleukin-2 fusion protein, a preparation method and its coding gene, a chicken long-acting interferon, and chicken albumin, chicken interferon-α and chicken interleukin-2 are connected through a flexible flexible linker , obtain chicken albumin-interferon-α-interleukin-2 fusion protein, design and optimize its coding gene, and finally prepare recombinant chicken long-acting interferon, which can significantly increase the half-life of chicken interferon, which is 20 times higher than that of common chicken interferon Above, and has broad-spectrum antiviral effect and can improve the immune response of chicken itself.